[go: up one dir, main page]

AU5939901A - Methods of treating vascular diseases characterized by nitric oxide insufficiency - Google Patents

Methods of treating vascular diseases characterized by nitric oxide insufficiency

Info

Publication number
AU5939901A
AU5939901A AU5939901A AU5939901A AU5939901A AU 5939901 A AU5939901 A AU 5939901A AU 5939901 A AU5939901 A AU 5939901A AU 5939901 A AU5939901 A AU 5939901A AU 5939901 A AU5939901 A AU 5939901A
Authority
AU
Australia
Prior art keywords
methods
nitric oxide
vascular diseases
diseases characterized
treating vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU5939901A
Inventor
Joseph Loscalzo
Joseph A Vita
Michael D Loberg
Manuel Worcel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Nitromed Inc
Original Assignee
Boston University
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/697,317 external-priority patent/US6635273B1/en
Application filed by Boston University, Nitromed Inc filed Critical Boston University
Publication of AU5939901A publication Critical patent/AU5939901A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU5939901A 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency Pending AU5939901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/697,317 US6635273B1 (en) 1999-10-29 2000-10-27 Methods of treating vascular diseases characterized by nitric oxide insufficiency
PCT/US2000/029528 WO2001035961A1 (en) 1999-10-29 2000-10-27 Methods of treating vascular diseases characterized by nitric oxide insufficiency
PCT/US2001/014245 WO2002034303A1 (en) 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency

Publications (1)

Publication Number Publication Date
AU5939901A true AU5939901A (en) 2002-05-06

Family

ID=27663595

Family Applications (3)

Application Number Title Priority Date Filing Date
AU5939901A Pending AU5939901A (en) 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2001259399A Ceased AU2001259399B2 (en) 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2006236103A Ceased AU2006236103B2 (en) 2000-10-27 2006-11-16 Methods of treating vascular diseases characterized by nitric oxide insufficiency

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2001259399A Ceased AU2001259399B2 (en) 2000-10-27 2001-05-02 Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2006236103A Ceased AU2006236103B2 (en) 2000-10-27 2006-11-16 Methods of treating vascular diseases characterized by nitric oxide insufficiency

Country Status (5)

Country Link
EP (1) EP1337283A4 (en)
JP (1) JP2004521083A (en)
AU (3) AU5939901A (en)
CA (2) CA2678256A1 (en)
WO (1) WO2002034303A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104366475A (en) * 2014-11-10 2015-02-25 罗会明 Enhanced health product

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383974A1 (en) 1999-09-08 2001-03-15 Nitromed Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
FR2832634A1 (en) * 2001-11-29 2003-05-30 Univ Pasteur USE OF L ISOMERS OF AMINOACID DERIVATIVES OF HYDROXYGUANIDINE FOR THE PRODUCTION OF NO, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PHARMACEUTICAL USES
WO2004050084A2 (en) * 2002-11-29 2004-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
WO2005004884A2 (en) 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
ES2258365B1 (en) * 2003-10-03 2007-12-01 Lacer, S.A. DERIVATIVES OF DISULFIDE, SULFIDE, SULFOXIDE AND SULFONE OF CYCLING SUGARS AND THEIR USES.
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
ITMI20032528A1 (en) * 2003-12-19 2005-06-20 Francesco Santangelo USE OF CYSTINE OR CISTEIN FOR PREVENTION AND THE
WO2005107384A2 (en) * 2004-03-31 2005-11-17 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
TW200612896A (en) * 2004-09-21 2006-05-01 Sankyo Co Pharmaceutical compositions containing with HMG-CoA reductase inhibitor and glutathione
JP4949661B2 (en) * 2004-09-21 2012-06-13 第一三共株式会社 Pharmaceutical composition containing HMG-CoA reductase inhibitor and glutathione
JP2008535858A (en) * 2005-04-07 2008-09-04 ニトロメッド インコーポレーティッド Method for assessing genetic risk in heart failure, ie, the effect of NOS3 gene mutation
US20070098796A1 (en) 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
US20070098791A1 (en) * 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
MX2008011842A (en) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Methods and compositions for treatment of diastolic heart failure.
AU2007254283A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
US20080138326A1 (en) 2006-12-06 2008-06-12 Kaneka Corporation Method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agents
ES2761224T3 (en) * 2012-02-15 2020-05-19 Kyowa Hakko Bio Co Ltd Agent to prevent or improve endothelial vascular dysfunction
EP2914257B1 (en) * 2012-10-30 2019-04-03 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
JP6531990B2 (en) 2013-02-28 2019-06-19 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Inorganic Nitrite to Improve Cardiopulmonary Hemodynamics
CN116410143A (en) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 A kind of multi-substituted uracil derivative and its preparation method and application
WO2023244805A1 (en) * 2022-06-16 2023-12-21 Georgia Tech Research Corporation Anti-vwf therapeutic for preventing arterial thrombi

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584315A (en) * 1981-11-16 1986-04-22 The Upjohn Company Method of treating ischemic states
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
DE68917946T2 (en) * 1988-01-29 1995-01-05 Peter H Proctor Hair growth stimulation with nitroxyd and other radicals.
DE4031881C2 (en) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Solvent-free, oral sustained-release pharmaceutical preparation and process for its preparation
AU673183B2 (en) * 1992-07-10 1996-10-31 Boots Company Plc, The Dioxcyclobutene derivatives as angiotensin II antagonists
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
IT1295694B1 (en) * 1996-11-14 1999-05-27 Nicox Sa NITROXIS DERIVATIVES FOR THE PREPARATION OF MEDICATIONS WITH ANTI-THROMBINIC ACTIVITY
JP4136029B2 (en) * 1997-05-12 2008-08-20 帝國製薬株式会社 Patch containing isosorbide nitrate
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
AU780261B2 (en) * 1999-10-29 2005-03-10 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104366475A (en) * 2014-11-10 2015-02-25 罗会明 Enhanced health product
CN104366475B (en) * 2014-11-10 2016-01-20 罗会明 A kind of enhancement mode health products

Also Published As

Publication number Publication date
CA2421885A1 (en) 2002-05-02
CA2678256A1 (en) 2002-05-02
JP2004521083A (en) 2004-07-15
AU2001259399B2 (en) 2006-08-17
EP1337283A1 (en) 2003-08-27
EP1337283A4 (en) 2005-05-18
AU2006236103A1 (en) 2006-12-07
WO2002034303A1 (en) 2002-05-02
AU2006236103B2 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
AU5939901A (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
GB2393202B (en) Methods of well treatment
EP1404343A4 (en) Therapeutic combinations for the treatment of hormone deficiencies
AU2001249881A1 (en) Method of treating the heart
EP1267798A4 (en) Treatment of skin damage using polyenylphosphatidylcholine
HU0001471D0 (en) New method of treatment
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
GB0004531D0 (en) The treatment of respiratory diseases
HUP0200738A3 (en) Method of the treatment of incontinence
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
EP1389105A4 (en) Method of treatment
IL150479A0 (en) Treatment of psoriasis
GB0124124D0 (en) Methods of treatment
IL155769A0 (en) Method for the treatment of inflammation
GB0112216D0 (en) Method of treatment
GB2360453B (en) Treatment of skin conditions
AU9545701A (en) Use of carp inhibitors for the treatment of heart diseases
AU6137801A (en) Method and composition for the treatment of angiogenesis
GB0008921D0 (en) Method of treatment
GB0020588D0 (en) Treatment of wounds
GB0118892D0 (en) Method of treatment
EP1402902A4 (en) Method for treatment of vascular regeneration
IL161630A0 (en) Methods of treating endometreosis